Your browser is no longer supported. Please, upgrade your browser.
Settings
AGN Allergan plc daily Stock Chart
AGN [NYSE]
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-22.57 Insider Own0.10% Shs Outstand333.50M Perf Week2.31%
Market Cap57.26B Forward P/E10.81 EPS next Y15.88 Insider Trans1.77% Shs Float331.77M Perf Month-0.79%
Income-7549.50M PEG- EPS next Q4.73 Inst Own85.30% Short Float3.02% Perf Quarter-22.51%
Sales15.48B P/S3.70 EPS this Y63.30% Inst Trans-1.33% Short Ratio2.57 Perf Half Y-27.77%
Book/sh198.59 P/B0.86 EPS next Y-2.29% ROA-6.00% Target Price227.29 Perf Year-10.87%
Cash/sh16.32 P/C10.52 EPS next 5Y7.99% ROE-10.80% 52W Range160.07 - 256.80 Perf YTD-18.25%
Dividend2.80 P/FCF22.97 EPS past 5Y-28.70% ROI0.10% 52W High-33.15% Beta1.10
Dividend %1.63% Quick Ratio1.10 Sales past 5Y26.00% Gross Margin86.60% 52W Low7.25% ATR4.62
Employees16700 Current Ratio1.20 Sales Q/Q11.40% Oper. Margin-65.70% RSI (14)48.14 Volatility2.82% 2.70%
OptionableYes Debt/Eq0.46 EPS Q/Q-948.20% Profit Margin-48.60% Rel Volume1.08 Prev Close170.94
ShortableYes LT Debt/Eq0.40 EarningsJan 31 BMO Payout- Avg Volume3.89M Price171.68
Recom2.20 SMA200.39% SMA50-4.70% SMA200-22.17% Volume4,200,938 Change0.43%
Dec-07-17Downgrade Argus Buy → Hold
Nov-29-17Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-27-17Resumed Leerink Partners Outperform $237
Nov-02-17Reiterated RBC Capital Mkts Outperform $250 → $221
Oct-19-17Reiterated RBC Capital Mkts Outperform $277 → $250
Oct-17-17Reiterated UBS Buy $275 → $255
Oct-02-17Reiterated Barclays Equal Weight
Sep-25-17Reiterated RBC Capital Mkts Outperform $285 → $277
Sep-20-17Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-16-17Initiated Cantor Fitzgerald Neutral $231
Jun-09-17Reiterated Mizuho Buy $275 → $267
May-10-17Reiterated RBC Capital Mkts Outperform $279 → $284
May-10-17Downgrade Goldman Buy → Neutral
Feb-09-17Reiterated Mizuho Buy $273 → $275
Dec-09-16Reiterated Credit Suisse Outperform $301 → $274
Nov-17-16Reiterated Mizuho Buy $293 → $273
Nov-03-16Reiterated RBC Capital Mkts Outperform $300 → $279
Nov-01-16Reiterated Mizuho Buy $299 → $293
Oct-31-16Resumed Barclays Equal Weight $250
Oct-11-16Reiterated Mizuho Buy $305 → $299
Dec-15-17 12:53PM  John Griffin: A Former Tiger Cub"s Wavering Fortunes GuruFocus.com
10:51AM  A Better Botox May Target Millennials, Men and Hesitant Women Bloomberg
Dec-14-17 03:51PM  Valeant: Down It Goes! Barrons.com
09:51AM  10 Biggest Antidepressant Drug Companies In 2017 Insider Monkey
Dec-13-17 09:57PM  U.S. appeals court vacates conviction of drug distributor over Botox Reuters
03:46PM  Allergan Inks Deal to Buy Texas-Based Repros Therapeutics Zacks
03:18PM  Woman-Led 'Drybar For Botox' Chain Alchemy 43 Grows -- With Drybar Founders' Backing Forbes
02:45PM  10 More Losers That Will Be Stocks to Buy in 2018 InvestorPlace
01:29AM  3 Drug/Biotech Stocks Up More Than 10% This Week Zacks
Dec-12-17 09:40AM  Allergan to buy Woodlands-based drug company American City Business Journals
08:51AM  Allergan Receives FDA Clearance For the CoolSculpting® Treatment To Improve Appearance Of Lax Tissue In The Double Chin PR Newswire
Dec-11-17 10:53AM  Weekly CEO Buys Highlight GuruFocus.com
10:30AM  Allergan on the Street: Analyst Recommendations This December Market Realist
09:01AM  What Are Analysts Estimating for Allergan Today? Market Realist
07:31AM  Inside Allergans International Segment in 3Q17 Market Realist
Dec-10-17 10:31AM  Weekly Top Insider Buys Highlight for the Week of Dec. 8 GuruFocus.com
Dec-08-17 03:33PM  Bill Ackman Likely to Face Trial on Allergan Insider-Trading Claims Bloomberg
02:22PM  3 Drug/Biotech Stocks Up More Than 10% This Week Zacks
12:17PM  ETFs with exposure to Allergan Plc : December 8, 2017 Capital Cube
10:31AM  Inside Allergans US General Medicines in 3Q17 Market Realist
09:02AM  Inside Allergans US Specialized Therapeutics in 3Q17 Market Realist
08:03AM  See what the IHS Markit Score report has to say about Allergan plc. Markit
07:33AM  Breaking down Allergans Business Segments in 3Q17 Market Realist
Dec-07-17 07:11PM  Cramer Remix: Yes, Allergan is the anti-bitcoin CNBC Videos
07:08PM  Cramer's lightning round: Energy Transfer Partners is wor... CNBC Videos
06:59PM  Cramer Remix: Yes, Allergan is the anti-bitcoin CNBC
05:30PM  Behind Allergans Revenues in 3Q17 Market Realist
03:57PM  Understanding Allergans Valuation in December 2017 Market Realist
12:18PM  Botox Competition Spurs Argus To Downgrade Allergan Benzinga
11:15AM  Allergan Plc (AGN) Chairman, President and CEO Brent L Saunders Bought $757,804 of Shares GuruFocus.com
Dec-06-17 07:56PM  Allergan Ends Positive After Selloff; Walgreens, Fred's Make Moves -- ICYMI TheStreet.com
03:08PM  Roche's Avastin Gets Full FDA Approval for Brain Cancer Zacks
02:10PM  Revance's Neuromodulator Injection Positive in Phase III Zacks
10:41AM  Fine Lines: Why Allergan's Botox Ain't Beat Barrons.com
08:00AM  Todays Research Reports on Stocks to Watch: Allergan plc and Galectin Therapeutics ACCESSWIRE
12:01AM  How Ackman Hopes to Beat Insider-Trading Lawsuit: QuickTake Q&A Bloomberg
Dec-05-17 05:34PM  Could This Smaller Biotech Rival Allergan's Blockbuster Botox? Investor's Business Daily
03:48PM  Why the Latest Data Is a Big Deal for Revance Therapeutics GuruFocus.com
01:24PM  Allergan's Quantitative Downgrade Weighs on Prices TheStreet.com
01:14PM  Beware, Botox: A longer-lasting wrinkle relaxer shows promise CNBC
12:45PM  This Botox Competitor Is on the Rise Bloomberg
12:41PM  Allergan Shares Tumble as Revance Reports Positive Data for Botox Rival TheStreet.com
12:16PM  UPDATE: Revance stock surges and Allergan drops on positive results for wrinkle injection MarketWatch
09:32AM  AstraZeneca's COPD Drug Succeeds in Label Expansion Study Zacks
09:05AM  Ironwood Succeeds in Diabetic Hypertension Phase II Study Zacks
Dec-04-17 05:19PM  Wallace Weitz Boosts DXC Technology, Allergan Holdings GuruFocus.com
07:35AM  GlaxoSmithKlines Valuation in November 2017 Market Realist
07:29AM  It made us look bad: Pharma CEOs clash over Allergan patent move MarketWatch
Dec-03-17 07:06AM  Weekend roundup: Tesla might be the next Amazon | A likely bitcoin crash | Private sector fights global warming MarketWatch
Dec-01-17 05:59PM  Tech firms tell patent court to ignore Allergan deal with tribe Reuters
02:11PM  Gauging Novartiss Valuation This November Market Realist
09:00AM  Heres how bad it might get for stocks if tax reform flops MarketWatch
Nov-30-17 06:28PM  Patent Move Was Nuts, Regeneron CEO Tells Allergan Chief Bloomberg
12:00PM  Hedge Fund Manager Who Bet on Botox Turns to Rival Bloomberg
Nov-29-17 02:35PM  Allergan Upgraded at Morgan Stanley, Stock Surges TheStreet.com
11:21AM  HHS nominee Azar declines to comment on Allergan patent move Reuters
10:14AM  Allergan: Smile! What Could Be Better Than Botox? Barrons.com
09:04AM  Morning Movers: Change at Chipotle; Upgrade for Allergan Barrons.com
08:48AM  Analyst Says Negative Allergan Headlines Are Priced In, Upgrades Stock Benzinga
08:47AM  Allergan shares jump after Morgan Stanley says fears of a 'better Botox' may be 'overdone' CNBC
08:47AM  Allergan shares jump after Morgan Stanley says fears of a 'better Botox' are overdone CNBC
08:01AM  Allergan's Migraine Leadership Recognized with Enrico Greppi Award for Excellence in Headache Research PR Newswire
07:29AM  Square and Allergan: Cramer's 'Off The Charts' TheStreet.com
03:56AM  How to Double Your Bond Returns Harvest Exchange
Nov-28-17 06:55PM  Cramer's charts show that the struggling stock of Square ... CNBC Videos
08:46AM  Teva's New CEO Re-Shuffles Senior Management, Stock Up 7% Zacks
07:40AM  Research Report Identifies Allergan, Johnson & Johnson, Ford Motor, CSX, Gamestop, and L Brands with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-27-17 07:10PM  Cramer's biggest investing mistakes CNBC Videos
07:00PM  Cramer admits his biggest investing mistakes CNBC Videos
06:45PM  Cramer admits his biggest investing mistakes CNBC
12:03PM  Heres why Apple, big pharma are paying attention to a Supreme Court case over a fracking patent CNBC
11:51AM  ETFs with exposure to Allergan Plc : November 27, 2017 Capital Cube
11:32AM  U.S. Supreme Court divided over legality of patent reviews Reuters
Nov-24-17 01:25PM  Teva (TEVA) Stock Rises 5% on Reports of Massive Job Cuts Zacks
Nov-23-17 10:32AM  Teva on the Street: Analyst Recommendations in November 2017 Market Realist
09:00AM  Top 10 Largest Pharmaceutical Companies By Revenue in 2017 Insider Monkey
Nov-22-17 04:15PM  Allergan to Present at the 2017 Citi Global Healthcare Conference PR Newswire
Nov-20-17 05:00PM  Merck's drug bust: 3 trades CNBC Videos
11:21AM  Top Stocks Billionaire David Tepper Bought and Sold in Q3: 13F Filing Investopedia
Nov-16-17 08:00AM  Allergan to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference PR Newswire
Nov-15-17 07:32AM  Inside Novartiss Ophthalmology Drugs Now Market Realist
06:33AM  An Undervalued, Wide-Moat Name in Healthcare Morningstar
Nov-14-17 08:15PM  Norwegian Cruise Line Holdings: Cramer's Top Takeaways TheStreet.com
04:16PM  Allergan's Vraylar Gets FDA Nod for Maintenance Therapy Zacks
02:54PM  Here's What's Behind Synergy Pharmaceuticals' 15.6% Drop Today Motley Fool
08:00AM  Overactive Bladder Causes Significant Burden, Regardless of Age Amongst Adults PR Newswire
Nov-13-17 03:37PM  Allergan to sell a quarter of its Teva stake in first quarter 2018 Reuters
08:57AM  Amgen Gets Positive CHMP Opinion to Expand Nplate's Label Zacks
07:45AM  Allergan wins FDA approval for use of Vraylar in maintenance treatment of schizophrenia MarketWatch
07:35AM  Allergan Receives FDA Approval For Use of VRAYLAR (cariprazine) in the Maintenance Treatment of Schizophrenia PR Newswire
Nov-10-17 07:27AM  Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer PR Newswire
Nov-09-17 07:55AM  Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus Zacks
Nov-08-17 08:00AM  Allergan to Present Dynamic Eye Care Data at American Academy of Ophthalmology Meeting in New Orleans PR Newswire
06:00AM  Why Neos Therapeutics Inc Rose 13.7% In October Motley Fool
Nov-07-17 03:51PM  U.S. senators press Allergan for details on patent deal with tribe Reuters
03:11PM  Senators question Allergan CEO on tribe patent deal CNBC
09:53AM  Teva's Stock Could Crash Another 50% After Debt Cut to Junk TheStreet.com
09:00AM  Allergan Keeps Heading Lower. Is It Time to Buy? Motley Fool
07:00AM  Allergan to Present at Credit Suisse 26th Annual Healthcare Conference PR Newswire
Nov-06-17 05:25PM  Teva Survives Price Cut As Billionaire Reportedly Mulls Stake Investor's Business Daily
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BODINE CHRIS WDirectorDec 07Buy164.773,030499,25317,098Dec 07 05:21 PM
SAUNDERS BRENT LChairman, President and CEODec 06Buy164.744,600757,794186,377Dec 06 12:31 PM
COUGHLIN CHRISTOPHER JDirectorDec 05Buy163.3010,0001,633,00014,446Dec 05 04:16 PM
Meury WilliamChief Commercial OfficerDec 01Option Exercise78.8811,807931,33668,828Dec 04 06:21 PM
Meury WilliamChief Commercial OfficerDec 01Sale173.8911,8072,053,11957,021Dec 04 06:21 PM
SAUNDERS BRENT LChairman, President and CEOJun 16Buy235.964410,327131,178Sep 18 08:49 PM
Basgoz NesliDirectorMay 18Option Exercise84.441,889159,5077,919May 22 04:26 PM
Basgoz NesliDirectorMay 18Sale220.451,889416,4306,030May 22 04:26 PM
GALLAGHER MICHAEL RDirectorMay 04Option Exercise245.2517,6934,339,20820,272May 05 06:34 PM
SAUNDERS BRENT LChairman, President and CEOMar 29Buy242.214310,299131,135Sep 18 08:49 PM
BISARO PAULDirectorMar 02Sale246.6870,00017,267,561235,900Mar 06 06:59 AM